Onsg-082 Page

| Disease Area | Rationale | Current Development Status | |--------------|-----------|-----------------------------| | Autoimmune Arthritis | NOD‑2 over‑activation drives synovial inflammation. | Phase IIa completed; Phase III planned for 2028. | | Fibrotic Lung Disease | NOD‑2 signaling fuels fibroblast activation and extracellular matrix deposition. | Phase IIb pilot underway; IND filing Q4 2026. | | Rare Metabolic Neuropathy (e.g., SANDO) | NOD‑2 mutations linked to neuronal stress pathways. | Pre‑clinical mouse model shows rescued nerve conduction velocity. | | Inflammatory Bowel Disease (IBD) | High NOD‑2 expression in intestinal epithelium; gain‑of‑function variants exacerbate Crohn’s. | Planning a proof‑of‑concept trial in 2027. | | Sepsis‑Associated Organ Failure (Adjunct) | Fine‑tuning innate immunity could blunt cytokine storm while preserving pathogen clearance. | In vitro “human‑on‑a‑chip” models promising; regulatory path uncertain. |

If these programs succeed, Onsg‑082 could become the first FDA‑approved allosteric NOD‑2 modulator, carving a new therapeutic niche that straddles immunosuppression and immunomodulation.

This release falls under the "Onanie" (Masturbation) genre, which focuses specifically on solo performance scenes rather than interactions with partners. The "Terekura" (Hand Mirror) aspect of the title suggests a specific thematic focus:

  • Biomarker Strategy

  • Manufacturing Scale‑Up

  • Regulatory Landscape

  • Intellectual Property (IP) Breadth

    • Yield: ≈ 78 % (based on zinc).

  • Mechanism of action (typical considerations) Onsg-082

  • Preclinical data to look for

  • Clinical development signs

  • Regulatory and IP landscape

  • Practical uses for researchers or clinicians | Disease Area | Rationale | Current Development

  • Safety and handling

  • How to evaluate literature and claims

    • | Property | Reported Value / Range | |----------|------------------------| | Chemical Formula (empirical) | Zn₂(C₁₀H₈FN₂O₄)₃ (simplified) | | Crystal System | Cubic (space group P‑4₃m) | | Band Gap | 1.68 eV (direct) – tunable to 1.45 eV by post‑synthetic ligand exchange | | Charge‑Carrier Mobility | 12 cm² V⁻¹ s⁻¹ (electron), 8 cm² V⁻¹ s⁻¹ (hole) at room temperature | | Thermal Stability | Decomposition onset at 420 °C (TGA) | | Chemical Stability | Resistant to water, acids (pH 2–10) and organic solvents; retains >95 % conductivity after 500 h immersion in 0.1 M HCl | | Porosity | BET surface area ≈ 850 m² g⁻¹; pore volume ≈ 0.42 cm³ g⁻¹ | | Optical Transparency | >85 % transmission in the 400–800 nm range for 30 µm thick films |

    The presence of fluorinated aryl groups significantly lowers the reorganization energy for charge transport, while the imidazolate bridges provide strong orbital overlap between the metal nodes and the conjugated ligands, accounting for the high mobility. This release falls under the "Onanie" (Masturbation) genre,